What is Zacks Research’s Forecast for CRL FY2028 Earnings?

Charles River Laboratories International, Inc. (NYSE:CRL) – Research analysts at Zacks Research boosted their FY2028 earnings per share (EPS) estimates for Charles River Laboratories International in a research report issued to clients and investors on Thursday, May 28th. Zacks Research analyst Team now anticipates that the medical research company will earn $13.01 per share for the year, up from their prior forecast of $12.13. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $11.04 per share.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The business had revenue of $995.83 million during the quarter, compared to analysts’ expectations of $977.46 million. During the same quarter in the prior year, the firm earned $2.34 earnings per share. The business’s revenue was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS.

Other equities analysts have also recently issued research reports about the company. JPMorgan Chase & Co. reduced their target price on Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Monday, April 13th. Robert W. Baird set a $213.00 target price on Charles River Laboratories International in a report on Friday, May 8th. UBS Group increased their target price on Charles River Laboratories International from $170.00 to $175.00 and gave the company a “neutral” rating in a report on Wednesday, February 25th. Weiss Ratings raised Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. Finally, Wall Street Zen cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. Eleven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $208.50.

Charles River Laboratories International Price Performance

Shares of Charles River Laboratories International stock opened at $181.06 on Monday. The business has a 50 day simple moving average of $169.08 and a two-hundred day simple moving average of $181.28. Charles River Laboratories International has a 12 month low of $132.58 and a 12 month high of $228.88. The stock has a market capitalization of $8.72 billion, a P/E ratio of -48.15, a PEG ratio of 2.07 and a beta of 1.46. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.36 and a quick ratio of 1.03.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Tema Etfs LLC purchased a new position in Charles River Laboratories International in the fourth quarter worth approximately $26,000. Rothschild Investment LLC grew its position in Charles River Laboratories International by 82.4% in the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after acquiring an additional 84 shares during the period. Atlantic Union Bankshares Corp purchased a new position in Charles River Laboratories International in the third quarter worth approximately $31,000. Los Angeles Capital Management LLC purchased a new position in Charles River Laboratories International in the fourth quarter worth approximately $42,000. Finally, Sfam LLC purchased a new position in Charles River Laboratories International in the fourth quarter worth approximately $43,000. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Key Charles River Laboratories International News

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Zacks Research increased its FY2026 EPS estimate for Charles River Laboratories International to $10.91 from $10.79, implying slightly better near-term earnings power.
• Positive Sentiment: The firm also lifted FY2027 EPS forecasts to $12.11 from $11.62 and raised several quarterly estimates, including Q2 2027, Q3 2027, Q4 2027, and Q1 2028, reinforcing a more optimistic longer-term outlook.
• Positive Sentiment: Zacks Research raised Q2 2026, Q3 2026, and Q4 2026 earnings estimates as well, suggesting momentum may be improving across the next several reporting periods.
• Neutral Sentiment: Brokerage sentiment remains constructive overall, with the stock previously noted as having a consensus “Moderate Buy” rating.
• Neutral Sentiment: Recent market commentary also pointed to a 5% share-price surge earlier this week, adding to already positive trading momentum.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.